论文部分内容阅读
目的 观察 FK— 5 0 6抑制全角膜移植术 (包括带环形巩膜瓣的全角膜移植术 )后免疫排斥反应的临床疗效。方法 对 76例 (76只眼 )全角膜移植术患者按随机原则分试验组 (FK— 5 0 6组 )及对照组 (Cs A组 )各 38例(38只眼 ) ,观察术后不同时期角膜移植术后角膜免疫排斥反应的发生率 ,平均随访时间 6个月。结果 全角膜移植术后 ,局部应用 FK— 5 0 6可有效抑制新生血管的发生 ;随访期内 ,治疗组 (FK— 5 0 6组 )移植片排斥反应发生率为6 8.4% ,而对照组 (Cs A组 )的排斥反应发生率为 92 .1% (u检验 ,P<0 .0 1) ,两组具有显著差异。结论 局部应用FK— 5 0 6可有效抑制高危角膜移植术后免疫排斥反应的发生 ,延长全角膜移植术后植片透明存活时间
Objective To observe the clinical effect of FK-506 on immune rejection after total corneal transplantation (including whole corneal transplantation with annular scleral flap). Methods Totally 76 patients (76 eyes) with total corneal allograft were randomly divided into three groups: 38 cases (38 eyes) in each group and 38 cases in control group (FK-506 group) The incidence of corneal immune rejection after keratoplasty was followed up for an average of 6 months. Results After total corneal transplantation, local application of FK-506 could effectively inhibit the occurrence of neovascularization. During the follow-up period, the incidence of rejection in the treatment group (FK-506) was 6 8.4%, while in the control group (CsA group) rejection rate was 92.1% (u test, P <0.01), the two groups were significantly different. Conclusion Topical application of FK-506 can effectively inhibit the occurrence of immunological rejection after high-risk corneal transplantation and prolong the time of transparent vitreous survival after total corneal transplantation